Biotest AG
BIESF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.53 | -0.02 | 0.96 | -0.22 |
| FCF Yield | 2.94% | -2.91% | -4.56% | 1.06% |
| EV / EBITDA | 13.16 | 9.58 | 80.55 | -102.00 |
| Quality | ||||
| ROIC | 4.18% | 13.63% | -1.57% | -4.61% |
| Gross Margin | 30.82% | 40.94% | 24.20% | 15.65% |
| Cash Conversion Ratio | 2.31 | -0.02 | -1.28 | -0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.06% | 9.91% | 2.15% | 7.15% |
| Free Cash Flow Growth | 189.20% | 48.28% | -544.59% | 135.93% |
| Safety | ||||
| Net Debt / EBITDA | 4.06 | 2.78 | 18.53 | -21.42 |
| Interest Coverage | 2.87 | 3.59 | -0.69 | -3.57 |
| Efficiency | ||||
| Inventory Turnover | 1.05 | 0.96 | 1.33 | 1.78 |
| Cash Conversion Cycle | 385.62 | 412.78 | 345.68 | 280.54 |